A Tainan-based research team from National Cheng Kung University (NCKU)
has discovered the pathogenesis of liver fibrosis and developed
antibodies that reduce liver damage, inhibit hepatic fibrosis, and
recover liver function.
Professor Ming-Shi Chang, PhD, Chair
Professor of Biochemistry and Molecular Biology at NCKU, has led the
team to make another breakthrough in their research on interleukin 20
(IL-20), the university revealed at a press conference on June 3.
Their
research titled “IL-20 and IL-20R1 Antibodies Protect Against Liver
Fibrosis” has been published in the May issue of Hepatology.
Currently,
NCKU has been granted a patent in the United States of America, US
860347 B1, “Use of IL-20 Antagonists for Treating Liver Diseases”, which
has attracted great interest from the biotechnology industry.
Read more... Labels: IL-20 and IL-20R1 Antibodies